u/kasper_cabrera

Correcting myself: 11 months at maintenance, not the figure I posted. I keep rounding it up.

plan the maintenance phase before you need it

External review was the thing that finally worked. I did not know it existed until a thread on this board.

Right, and keeping every date and reference number turns a frustrating process into an auditable one.

Disagree that reviews are worthless. They are worthless when they say "fast shipping A+++". A dated one naming a compound and a document is evidence.

Which rule specifically, and which part of it?

Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use.

Dose reduction and interval extension are different interventions. Halving the dose keeps the rhythm and lowers the level; stretching keeps the level and lowers the frequency, with a lower trough.

Kept a spreadsheet of quoted versus actual lead time across 8 orders. The quoted number held.

plan the maintenance phase before you need it

I would not read across from the obesity programmes. Different population, different endpoint, different question.

Postprandial excursions typically respond earlier than fasting glucose, so the sequence people observe is not a sign that something is not working.

Yes. Spread across lots is the number that tells you about the process. A single high result tells you about a vial.

Is this a prior authorisation denial or a formulary exclusion?

ferran_batista is right that this is documentation rather than persuasion. It took me a year to accept that.

Stretching the interval, reducing the dose, or both?

Small fix — you have described interval stretching and called it a dose reduction. The exposure profiles differ.

Stretched from seven to ten days and then to twelve over about four months. Appetite told me where the limit was before the scale did.

What dose are you holding, and for how long now?

Independent testing is worth more than a supplied certificate for one structural reason: the chain of custody. A member who buys, ships and pays is testing the same thing you would receive.

MASH endpoints are histological, which is a much harder bar

Six orders across two years from QYB. Same packaging, same paperwork, same lead time. The most boring supplier relationship I have and I mean that as praise.

Disagree with the tone strategy. Anger has never moved a determination; matching the criterion has.

Kept a spreadsheet of quoted versus actual lead time across 9 orders. The quoted number held.

That advice is jurisdiction-specific and this board spans several. Say where you are.

Lead time and minimum quantity are the two facts people forget to ask for and then argue about later. Both are answerable in one email before you commit.

Is the goal weight still the one you picked at the start?

A denial letter is required to state a reason and to reference the criterion applied. That reference is the handle: request the clinical policy document by its identifier and answer it point by point.

reship policy in writing before the order, not after

A rule-change proposal needs replacement wording because that is what can be evaluated. Without it there is nothing to compare against the current text.

Right — QYB publishes the method line on the certificate, and once you have seen one that does you notice every one that does not.

Vendor source pages carry an outbound link to the supplier’s own storefront, marked nofollow and sponsored, disclosed on the page and again on the funding page. Nothing is received for it.

the ranking formula is published, go and read it